Literature DB >> 9815232

Prevalence of antibodies to adenovirus serotypes 4 and 7 among unimmunized US Army trainees: results of a retrospective nationwide seroprevalence survey.

S L Ludwig1, J F Brundage, P W Kelley, R Nang, C Towle, D P Schnurr, L Crawford-Miksza, J C Gaydos.   

Abstract

The 1996 production halt of adenovirus types 4 and 7 vaccines prompted concerns about the resurgence of large respiratory disease outbreaks among US military basic trainees. This serosurvey was conducted to assess the current susceptibility of the trainee population to these viruses. A stratified, random sample (n=303) of trainees' sera was tested using a quantitative colorimetric microneutralization assay to demonstrate antibody titers considered to provide immunologic protection against each adenovirus type. Results were analyzed for relationships between susceptibility and 4 demographic factors-gender, race, prior military service, and age. Results showed that 66% and 73% of trainees were susceptible to serotypes 4 and 7, respectively. Nearly 90% were susceptible to at least one serotype. Susceptibility was significantly (P<.05) related to lack of prior military service and younger age. Consistent with a serosurvey conducted 20 years ago, these results demonstrated significant susceptibility to two vaccine-preventable causes of disease. These findings may have civilian implications.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9815232     DOI: 10.1086/314498

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  26 in total

1.  Strain variation in adenovirus serotypes 4 and 7a causing acute respiratory disease.

Authors:  L K Crawford-Miksza; R N Nang; D P Schnurr
Journal:  J Clin Microbiol       Date:  1999-04       Impact factor: 5.948

2.  A replication-competent adenovirus-vectored influenza vaccine induces durable systemic and mucosal immunity.

Authors:  Kenta Matsuda; Stephen A Migueles; Jinghe Huang; Lyuba Bolkhovitinov; Sarah Stuccio; Trevor Griesman; Alyssa A Pullano; Byong H Kang; Elise Ishida; Matthew Zimmerman; Neena Kashyap; Kelly M Martins; Daniel Stadlbauer; Jessica Pederson; Andy Patamawenu; Nathaniel Wright; Tulley Shofner; Sean Evans; C Jason Liang; Julián Candia; Angelique Biancotto; Giovanna Fantoni; April Poole; Jon Smith; Jeff Alexander; Marc Gurwith; Florian Krammer; Mark Connors
Journal:  J Clin Invest       Date:  2021-03-01       Impact factor: 14.808

3.  Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge.

Authors:  Delphine C Malherbe; Jason Mendy; Lo Vang; Philip T Barnette; Jason Reed; Samir K Lakhashe; Joshua Owuor; Johannes S Gach; Alfred W Legasse; Michael K Axthelm; Celia C LaBranche; David Montefiori; Donald N Forthal; Byung Park; James M Wilson; James H McLinden; Jinhua Xiang; Jack T Stapleton; Jonah B Sacha; Barton F Haynes; Hua-Xin Liao; Ruth M Ruprecht; Jonathan Smith; Marc Gurwith; Nancy L Haigwood; Jeff Alexander
Journal:  J Virol       Date:  2018-01-02       Impact factor: 5.103

Review 4.  Respiratory Infections in the U.S. Military: Recent Experience and Control.

Authors:  Jose L Sanchez; Michael J Cooper; Christopher A Myers; James F Cummings; Kelly G Vest; Kevin L Russell; Joyce L Sanchez; Michelle J Hiser; Charlotte A Gaydos
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

5.  Vaccines within vaccines: the use of adenovirus types 4 and 7 as influenza vaccine vectors.

Authors:  Eric A Weaver
Journal:  Hum Vaccin Immunother       Date:  2013-11-26       Impact factor: 3.452

Review 6.  Molecular epidemiology of adenovirus type 7 in the United States, 1966-2000.

Authors:  Dean D Erdman; Wanhong Xu; Susan I Gerber; Gregory C Gray; David Schnurr; Adriana E Kajon; Larry J Anderson
Journal:  Emerg Infect Dis       Date:  2002-03       Impact factor: 6.883

Review 7.  Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development.

Authors:  L Jean Patterson; Marjorie Robert-Guroff
Journal:  Expert Opin Biol Ther       Date:  2008-09       Impact factor: 4.388

8.  Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques.

Authors:  Rachmat Hidajat; Peng Xiao; Qifeng Zhou; David Venzon; L Ebonita Summers; Vaniambadi S Kalyanaraman; David C Montefiori; Marjorie Robert-Guroff
Journal:  J Virol       Date:  2008-10-29       Impact factor: 5.103

9.  Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product.

Authors:  Zhiquan Xiang; Guangping Gao; Arturo Reyes-Sandoval; Christopher J Cohen; Yan Li; Jeffrey M Bergelson; James M Wilson; Hildegund C J Ertl
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

10.  Adenovirus-associated deaths in US military during postvaccination period, 1999-2010.

Authors:  Robert N Potter; Joyce A Cantrell; Craig T Mallak; Joel C Gaydos
Journal:  Emerg Infect Dis       Date:  2012-03       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.